You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

ALLOPURINOL Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Allopurinol patents expire, and what generic alternatives are available?

Allopurinol is a drug marketed by Accord Hlthcare, Aiping Pharm Inc, Chartwell, Endo Operations, Harman Finochem, Hetero Labs Ltd V, Indoco, Ipca Labs Ltd, Lupin Ltd, Mutual Pharm, Mylan, Northstar Hlthcare, Puracap Pharm, Purepac Pharm, Sandoz, Sun Pharm Inds Inc, Sun Pharm Industries, Superpharm, Unichem, Watson Labs, Zydus Pharms, Gland Pharma Ltd, and Hikma. and is included in thirty NDAs.

The generic ingredient in ALLOPURINOL is allopurinol sodium. There are twenty-two drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the allopurinol sodium profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Allopurinol

A generic version of ALLOPURINOL was approved as allopurinol sodium by HIKMA on August 26th, 2004.

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ALLOPURINOL?
  • What are the global sales for ALLOPURINOL?
  • What is Average Wholesale Price for ALLOPURINOL?
Drug patent expirations by year for ALLOPURINOL
Drug Prices for ALLOPURINOL

See drug prices for ALLOPURINOL

Drug Sales Revenue Trends for ALLOPURINOL

See drug sales revenues for ALLOPURINOL

Recent Clinical Trials for ALLOPURINOL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Urica Therapeutics Inc.Phase 1/Phase 2
Dana-Farber Cancer InstitutePhase 2
Eli Lilly and CompanyPhase 2

See all ALLOPURINOL clinical trials

Pharmacology for ALLOPURINOL
Medical Subject Heading (MeSH) Categories for ALLOPURINOL

US Patents and Regulatory Information for ALLOPURINOL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Watson Labs ALLOPURINOL allopurinol TABLET;ORAL 018241-002 Nov 16, 1984 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Sun Pharm Industries ALLOPURINOL allopurinol TABLET;ORAL 071450-002 Jan 9, 1987 AB RX No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Zydus Pharms ALLOPURINOL allopurinol TABLET;ORAL 210117-002 Oct 12, 2017 AB RX No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Purepac Pharm ALLOPURINOL allopurinol TABLET;ORAL 070580-001 Apr 14, 1986 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

ALLOPURINOL Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Allopurinol

Introduction to Allopurinol

Allopurinol is a prescription medication used to treat high levels of uric acid in the body, which can lead to conditions such as gout and kidney stones. It is also utilized to manage uric acid levels in patients undergoing cancer treatment. Available in both oral tablet and intravenous forms, allopurinol is a xanthine oxidase inhibitor that reduces uric acid synthesis in the body[1][4].

Market Growth and Forecast

The global allopurinol market is anticipated to experience significant growth over the forecast period of 2022-2029. According to Data Bridge Market Research, the market is expected to grow at a Compound Annual Growth Rate (CAGR) of 6% during this period. This growth is driven by several key factors, including the increasing incidence of gout and kidney stones, a rising geriatric population, and growing healthcare expenditure[1].

Key Drivers of Market Growth

  • Increasing Incidence of Gout and Kidney Stones: The rise in the number of people suffering from gout and kidney stones is a major driver for the expansion of the allopurinol market. These conditions are becoming more prevalent due to factors such as obesity, unhealthy lifestyle, and increasing alcohol consumption[1][4].
  • Rising Geriatric Population: The growing elderly population is another significant factor, as older adults are more prone to developing gout and other uric acid-related disorders.
  • Growing Healthcare Expenditure: Increased healthcare spending and better healthcare infrastructure, particularly in regions like North America, are also contributing to market growth[1][4].

Market Segmentation

The allopurinol market is segmented based on several criteria, including:

  • Drug Class: Antigout agents and antihyperuricemic agents.
  • Application: Gout, kidney stones, and other conditions.
  • Demographic: Adult and pediatric populations.
  • Dosage Form: Intravenous powder for injection and oral tablets.
  • End-Users: Clinics, hospitals, and other healthcare facilities.
  • Distribution Channel: Hospital pharmacy, retail pharmacy, and online pharmacy[1].

Geographical Analysis

  • North America: This region dominates the allopurinol market due to the presence of major key players, high disposable income, and well-developed healthcare infrastructure. North America accounted for the largest market share in 2020 and is expected to continue its dominance[1][4].
  • Asia-Pacific: This region is expected to grow significantly during the forecast period due to increasing research and development activities and growing government support. The rise in gout incidences, driven by factors like increasing alcohol consumption and unhealthy lifestyles, is also a key factor in this region[1][4].

Financial Considerations and Cost Analysis

The cost of allopurinol can vary based on several factors, including treatment plan, insurance coverage, and the pharmacy used.

  • Cost Without Insurance: The price of allopurinol without insurance is typically higher. Factors affecting the cost include the quantity prescribed, dosage, and pharmacy used[2].
  • Generic vs. Brand Name: Allopurinol is available as both generic and brand-name drugs (Zyloprim, Lopurin, and Aloprim). Generic versions are generally cheaper and considered as safe and effective as the brand-name counterparts[2].
  • Savings Options: Patients can save money by using coupons, getting a 90-day supply, or using mail-order pharmacies. Financial assistance programs and savings cards are also available to help reduce costs[2].

Challenges and Restraints

Despite the positive growth outlook, the allopurinol market faces several challenges:

  • High Cost of the Drug: The high cost of allopurinol, especially for those without insurance, can be a significant barrier.
  • Side Effects: Allopurinol is associated with various side effects such as loss of appetite, dizziness, fever, chills, blood in urine, and skin rash, which can hamper market growth.
  • Lack of Awareness: Limited awareness about the drug and its benefits in certain regions can also pose a challenge[1].

Competitive Landscape

The global allopurinol market is competitive, with several key players operating in the space. These include:

  • Casper Pharma
  • Teva Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories
  • Mylan N.V.
  • Apotex Inc.
  • Sun Pharmaceutical Industries Limited
  • Zydus Pharmaceuticals Inc.
  • NorthStar Healthcare
  • Ipca Laboratories Limited
  • Accord Healthcare Ltd.[4].

Emerging Opportunities

  • Research and Development: Increasing research and development activities, particularly in emerging markets, provide beneficial opportunities for the allopurinol market.
  • New Markets: The emergence of new markets and growing government support in regions like Asia-Pacific are expected to drive market growth[1][4].

Impact of COVID-19

The COVID-19 pandemic had a short-term impact on the allopurinol market due to lockdowns, travel restrictions, and supply chain disruptions. However, the market is expected to recover and continue its growth trajectory as these disruptions are mitigated[4].

Comparison with Other Treatments

Allopurinol is often compared with other treatments for hyperuricaemia, such as febuxostat. Febuxostat has been shown to be more effective than allopurinol in reducing serum urate levels, especially in patients with impaired renal function. However, febuxostat also comes with its own set of side effects and considerations[5].

Key Takeaways

  • The global allopurinol market is expected to grow at a CAGR of 6% from 2022 to 2029.
  • Key drivers include the increasing incidence of gout and kidney stones, a rising geriatric population, and growing healthcare expenditure.
  • North America dominates the market, but Asia-Pacific is expected to grow significantly.
  • The cost of allopurinol varies based on insurance, dosage, and pharmacy used.
  • Challenges include high drug costs, side effects, and lack of awareness.
  • Emerging opportunities lie in research and development and new market emergence.

Frequently Asked Questions (FAQs)

What is the primary use of allopurinol?

Allopurinol is primarily used to treat high levels of uric acid in the body, which can lead to conditions such as gout and kidney stones. It is also used to manage uric acid levels in patients undergoing cancer treatment[1][4].

How does the cost of allopurinol vary?

The cost of allopurinol can vary based on several factors, including treatment plan, insurance coverage, dosage, and the pharmacy used. Generic versions are generally cheaper than brand-name drugs[2].

What are the common side effects of allopurinol?

Common side effects of allopurinol include loss of appetite, dizziness, fever, chills, blood in urine, and skin rash[1].

Which regions are expected to drive the growth of the allopurinol market?

North America currently dominates the allopurinol market, but the Asia-Pacific region is expected to grow significantly during the forecast period due to increasing research and development activities and growing government support[1][4].

How does allopurinol compare with other treatments like febuxostat?

Allopurinol is often compared with febuxostat, which has been shown to be more effective in reducing serum urate levels, especially in patients with impaired renal function. However, febuxostat also has its own set of side effects and considerations[5].

Cited Sources:

  1. Data Bridge Market Research. Global Allopurinol Market - Industry Trends and Forecast to 2029.
  2. Medical News Today. Allopurinol cost 2024: Savings tips and more.
  3. News Channel Nebraska. Gout Drugs Market Growth to Attain 14.79% by 2032.
  4. Stratview Research. Allopurinol Tablets Market | Market Size, Share & Forecast Analysis.
  5. Rheumatology. Febuxostat: a new treatment for hyperuricaemia in gout.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.